Ilex Medical
Ilex Medical Ltd provides healthcare technological solutions in Israel, South Africa, and internationally. The company offers microbiology, chemistry, molecular biology, immunochemistry, and blood banking solutions. It also offers coagulation, hematology, blood gases, bilirubin, biomarkers, fertility, cellular medicine occult blood, and calprotectin services, as well as provides LIS, urine micros… Read more
Ilex Medical (ILX) - Net Assets
Latest net assets as of June 2025: ILA660.36 Million ILA
Based on the latest financial reports, Ilex Medical (ILX) has net assets worth ILA660.36 Million ILA as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (ILA947.26 Million) and total liabilities (ILA286.90 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ILA660.36 Million |
| % of Total Assets | 69.71% |
| Annual Growth Rate | 11.74% |
| 5-Year Change | 45.76% |
| 10-Year Change | 186.07% |
| Growth Volatility | 33.39 |
Ilex Medical - Net Assets Trend (2008–2024)
This chart illustrates how Ilex Medical's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Ilex Medical (2008–2024)
The table below shows the annual net assets of Ilex Medical from 2008 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ILA646.49 Million | +3.69% |
| 2023-12-31 | ILA623.51 Million | +1.70% |
| 2022-12-31 | ILA613.10 Million | +6.52% |
| 2021-12-31 | ILA575.57 Million | +29.77% |
| 2020-12-31 | ILA443.54 Million | +37.12% |
| 2019-12-31 | ILA323.48 Million | +10.22% |
| 2018-12-31 | ILA293.49 Million | +10.27% |
| 2017-12-31 | ILA266.15 Million | +8.85% |
| 2016-12-31 | ILA244.51 Million | +8.19% |
| 2015-12-31 | ILA225.99 Million | +10.45% |
| 2014-12-31 | ILA204.60 Million | -4.56% |
| 2013-12-31 | ILA214.38 Million | -17.53% |
| 2012-12-31 | ILA259.96 Million | -8.14% |
| 2011-12-31 | ILA282.99 Million | +134.26% |
| 2010-12-31 | ILA120.80 Million | -5.12% |
| 2009-12-31 | ILA127.32 Million | +16.33% |
| 2008-12-31 | ILA109.44 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Ilex Medical's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 520.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ILA568.58 Million | 87.95% |
| Other Components | ILA77.91 Million | 12.05% |
| Total Equity | ILA646.49 Million | 100.00% |
Ilex Medical Competitors by Market Cap
The table below lists competitors of Ilex Medical ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
WestMountain Gold Inc
PINK:WMTN
|
$2.01 Million |
|
Dotz SA
SA:DOTZ3
|
$2.01 Million |
|
DO & CO
BE:DOQ
|
$2.01 Million |
|
Tidewater Midstream and Infrastructure Ltd
PINK:TWMIF
|
$2.02 Million |
|
Laxmi Cotspin Limited
NSE:LAXMICOT
|
$2.01 Million |
|
Nagreeka Exports Limited
NSE:NAGREEKEXP
|
$2.01 Million |
|
Wawasan Dengkil Holdings Berhad
KLSE:0347
|
$2.01 Million |
|
Jourdan Resources Inc
PINK:JORFF
|
$2.01 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ilex Medical's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 623,506,000 to 646,487,000, a change of 22,981,000 (3.7%).
- Net income of 38,981,000 contributed positively to equity growth.
- Dividend payments of 15,266,000 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ILA38.98 Million | +6.03% |
| Dividends Paid | ILA15.27 Million | -2.36% |
| Other Changes | ILA-734.00K | -0.11% |
| Total Change | ILA- | 3.69% |
Book Value vs Market Value Analysis
This analysis compares Ilex Medical's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 105.20x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 321.36x to 105.20x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | ILA18.92 | ILA6079.00 | x |
| 2019-12-31 | ILA22.20 | ILA6079.00 | x |
| 2020-12-31 | ILA39.32 | ILA6079.00 | x |
| 2021-12-31 | ILA51.02 | ILA6079.00 | x |
| 2022-12-31 | ILA54.35 | ILA6079.00 | x |
| 2023-12-31 | ILA55.27 | ILA6079.00 | x |
| 2024-12-31 | ILA57.78 | ILA6079.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ilex Medical utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.03%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.24%
- • Asset Turnover: 0.93x
- • Equity Multiplier: 1.54x
- Recent ROE (6.03%) is below the historical average (18.69%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | 17.00% | 8.75% | 1.25x | 1.55x | ILA7.67 Million |
| 2009 | 23.66% | 12.30% | 1.27x | 1.52x | ILA17.39 Million |
| 2010 | 23.88% | 11.67% | 1.29x | 1.59x | ILA16.77 Million |
| 2011 | 23.36% | 7.60% | 0.63x | 4.91x | ILA18.71 Million |
| 2013 | -25.66% | -4.81% | 0.86x | 6.17x | ILA-30.87 Million |
| 2014 | 24.05% | 5.11% | 0.85x | 5.51x | ILA12.91 Million |
| 2015 | 25.99% | 6.25% | 1.03x | 4.02x | ILA19.14 Million |
| 2016 | 19.60% | 5.33% | 1.06x | 3.46x | ILA13.54 Million |
| 2017 | 23.04% | 6.76% | 1.14x | 2.99x | ILA21.17 Million |
| 2018 | 24.75% | 7.82% | 1.13x | 2.81x | ILA28.00 Million |
| 2019 | 27.05% | 9.50% | 1.09x | 2.61x | ILA37.98 Million |
| 2020 | 27.20% | 12.74% | 1.21x | 1.76x | ILA76.27 Million |
| 2021 | 34.31% | 18.61% | 1.21x | 1.52x | ILA139.92 Million |
| 2022 | 16.66% | 11.70% | 0.97x | 1.47x | ILA40.81 Million |
| 2023 | 8.16% | 5.55% | 0.90x | 1.63x | ILA-11.47 Million |
| 2024 | 6.03% | 4.24% | 0.93x | 1.54x | ILA-25.67 Million |
Industry Comparison
This section compares Ilex Medical's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $38,594,111
- Average return on equity (ROE) among peers: -7.91%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ilex Medical (ILX) | ILA660.36 Million | 17.00% | 0.43x | $2.01 Million |
| Allmed Solutions Ltd (ALMD) | $45.13 Million | -46.38% | 0.26x | $96.61K |
| Erika Carmel Ltd (BCUR) | $8.97 Million | 138.94% | 4.32x | $46.92K |
| Bio-View Ltd (BIOV) | $23.45 Million | -5.34% | 0.48x | $54.59K |
| Erech Finance Cahalacha Ltd (EFNC) | $-63.00K | 0.00% | 0.00x | $19.28K |
| Endymed (ENDY) | $14.70 Million | 5.78% | 0.34x | $118.10K |
| Epitomee Medical Ltd (EPIT) | $34.80 Million | -16.33% | 0.16x | $567.43K |
| Human Xtensions Ltd (HUMX) | $61.78 Million | -72.18% | 0.17x | $21.16K |
| Pulsenmore Ltd (PULS) | $132.23 Million | -44.29% | 0.36x | $321.83K |
| Sofwave Medical Ltd (SOFW) | $26.34 Million | -31.42% | 0.65x | $3.18 Million |